Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of tafamidis in transthyretin cardiomyopathy
NL-OMON53130Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tafamidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Pfizer. Primary endpoints: All-cause mortality and Treatment-emergent adverse events. Started Jan 2018; status: active, not recruiting.
02
Drugs
tafamidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON53130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53130.